BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright ©The Author(s) 2025.
World J Hepatol. Nov 27, 2025; 17(11): 109051
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.109051
Table 1 PANoptosis and cancer therapeutic strategies
Potential therapeutic strategy
Name
Effect
Mechanism
Ref.
Traditional laboratory therapyTNF-α/IFN-γ-Triggers a PANoptosis cascade, exhibiting anti-tumor activity[44]
+May promote immune escape by inhibiting T-cell function-
KLX-Induces PANoptosis by altering ZBP1 conformation.[26]
PPDPF-Regulates TRIM21 to ubiquitinate RIPK1, further inhibiting HCC progression[78]
OTULIN-Inhibits FADD/RIPK1-mediated hepatocyte apoptosis, protecting liver cells and preventing liver inflammation and HCC [77]
DNASE1 L3-Activates the AIM2 pathway, thereby inducing PANoptosis[35]
HMOX1+Silencing reduces HCC resistance to sorafenib[92]
Fn-OMV/oHSV-Combined use enhances inflammatory responses and improves immune checkpoint blockade (ICB) efficacy[93]
ADAR1+Blocking ADAR1 activates ZBP1-mediated PANoptosis, inhibiting tumorigenesis[94]
Novel nanotherapiesBi2Sn2O7-Through ultrasound-responsive catalytic effects, generates enhanced enzyme kinetic effects for HCC treatment and inhibition of later-stage lung metastasis; also targets mitochondrial disruption, disrupting energy metabolism and amplifying ROS levels[95]
Fullerenols-Affects mitochondrial function and induces endoplasmic reticulum stress[96]